This article was paid for by Sam's Club. When you buy through our links, we earn a commission. Chrissy Callahan Contributing Reporter Sam’s Club is running an exclusive savings event for members ...
Panelists discuss how the treatment landscape for EGFR-mutated lung cancer has evolved, with 3 strong options now available, including single-agent osimertinib and 2 combinations: osimertinib plus ...
Panelists discuss insights from the MARIPOSA study on first-line treatment options for EGFR-mutant metastatic non–small cell lung cancer (NSCLC), highlighting the efficacy of amivantamab-lazertinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results